ContraVir names board member
Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
ContraVir Pharmaceuticals Inc. appointed Tamar Howson to its board.
Howson previously served as senior vice president of corporate and business development at both GlaxoSmithKline PLC and Bristol-Myers Squibb Co.
